Chrna7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CHRNA7 |
|---|
| Full Name | Cholinergic Receptor Nicotinic Alpha 7 Subunit |
|---|
| Chromosome | 15q13.3 |
|---|
| NCBI Gene ID | 1139 |
|---|
| OMIM | 100511 |
|---|
| Ensembl ID | ENSG00000175344 |
|---|
| UniProt ID | P36544 |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Epilepsy, Rett Syndrome |
|---|
The nicotinic acetylcholine receptor alpha 7 (α7 nAChR) is a homomeric ligand-gated ion channel highly expressed in the brain, particularly in the hippocampus, cortex, and basal ganglia. α7 nAChR exhibits high calcium permeability and rapidly desensitizes upon agonist binding. It plays crucial roles in cognitive functions including attention, memory, and learning. In Alzheimer's disease, α7 nAChR density is reduced in the hippocampus, and the receptor interacts with amyloid-beta, contributing to synaptic dysfunction. Agonists of α7 nAChR (including nicotine) have shown promise in preclinical models for enhancing cognition and providing neuroprotection.
The CHRNA7 gene spans approximately 45 kb on chromosome 15q13.3 and consists of 10 exons. The gene encodes a protein of 502 amino acids. Alternative splicing produces multiple transcript variants, with the canonical isoform being the most widely expressed. The promoter region contains binding sites for multiple transcription factors including SP1, AP2, and NF-κB, suggesting regulation by neuronal activity and inflammatory signals.
The α7 nAChR is a pentameric ligand-gated ion channel composed of five identical α7 subunits. Each subunit contains:
- Extracellular N-terminal domain: Contains the ligand-binding site at the interface between subunits
- Transmembrane domains (M1-M4): Four α-helical transmembrane segments that form the ion channel pore
- Intracellular loop: Between M3 and M4, contains sites for post-translational modifications
- C-terminal domain: Short cytoplasmic tail
The receptor has high permeability to calcium (PCa/PNa ≈ 10-20), making it uniquely positioned to activate intracellular calcium-dependent signaling pathways including CaMKII, PKC, and MAPK.
- Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Cortex: Layer-specific expression, highest in layers II-III and V
- Basal ganglia: Moderate expression in striatum and nucleus accumbens
- Thalamus: Specific nuclei show expression
- Olfactory bulb: High expression in mitral and tufted cells
- Autonomic ganglia
- Immune cells (macrophages, T-cells)
- Sensory neurons
- Pineal gland
- Agonist binding → conformational change → channel opening → Na⁺ and Ca²⁺ influx
- Calcium influx → activates CaMKII → phosphorylation of AMPA receptors and CREB
- MAPK/ERK activation → gene transcription → synaptic plasticity
- PI3K/Akt pathway → anti-apoptotic signaling → neuronal survival
- Aβ interaction: α7 nAChR binds amyloid-beta with high affinity, leading to receptor internalization and dysfunction
- JNK pathway: Activation leads to apoptosis
- GABAergic modulation: α7 nAChR on interneurons modulates inhibition
- Receptor loss: 30-50% reduction in α7 nAChR density in AD hippocampus
- Aβ interaction: Aβ1-42 binds α7 nAChR, disrupts signaling and promotes toxicity
- Calcium dysregulation: Loss of α7 function contributes to calcium homeostasis failure
- Cognitive decline: Correlates with memory deficits
- Nigrostriatal involvement: α7 nAChR on dopaminergic neurons may be affected
- Neuroprotection: Nicotinic agonists show protective effects in PD models
- Levodopa-induced dyskinesias: α7 nAChR antagonists may reduce dyskinesias
- Schizophrenia: CHRNA7 copy number variations and expression changes
- Rett Syndrome: MECP2 regulates CHRNA7 expression
- Epilepsy: Altered expression in epileptic tissue
| Drug/Compound |
Status |
Notes |
| PNU-282987 |
Research |
Selective α7 agonist |
| A-582941 |
Research |
Brain-penetrant agonist |
| EVP-6124 |
Clinical Trials |
Cognitive enhancement in AD |
| GTS-21 |
Clinical Trials |
Schizophrenia cogition |
- Enhance agonist efficacy without directly activating
- Fewer side effects than direct agonists
- Examples: CCMI, LY2087101
- Used to study receptor function
- Methyllycaconitine (MLA) is a selective antagonist
- CHRNA7 knockout mice: Show learning deficits, reduced hippocampal plasticity
- α7 overexpressing mice: Enhanced cognition, neuroprotection against Aβ
- Transgenic AD models: Crossbreeding with α7 mutants reveals interaction
Several clinical trials have evaluated α7 nAChR agonists:
- EVP-6124: Phase II showed cognitive improvement in AD
- RG3487: Phase II for schizophrenia
- A-582941: Phase I completed
The study of Chrna7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- 1 CHRNA7 gene. NCBI Gene. Retrieved 2026-03-04.
- 2 UniProtKB: P36544. Retrieved 2026-03-04.
- 3 Ensembl: ENSG00000175344. Retrieved 2026-03-04.
- 4 Dineley KT, et al. (2015). α7 nicotinic receptors in Alzheimer's disease. Pharmacol Rev.
- 5 Liu Q, et al. (2019). α7 nAChR agonists for cognitive enhancement. Neuropharmacology.
- 6 Wallace TL, et al. (2011). α7 nicotinic agonists for schizophrenia. Biol Psychiatry.
- 7 Gotti C, et al. (2009). α7 nAChR subtypes in brain. Neuropharmacology.
- 8 Changeux JP. (2012). Nicotinic receptors and Alzheimer's disease. J Mol Neurosci.